Pharmaco - Press Releases

Date	Title	Company
09-Dec-2019	Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors	Nouscom
09-Dec-2019	HVIVO (“HVIVO”) to merge with OPEN ORPHAN PLC (“OPEN ORPHAN”)	The Boards of Open Orphan and hVIVO
09-Dec-2019	Moberg Pharma meets primary endpoint for MOB-015 in a Phase 3 study for the treatment of onychomycosis	Moberg Pharma AB
09-Dec-2019	Eisai Presents New Seizure Freedom and Adherence Data Related to Anti-Epileptic Drug FYCOMPA® at the 2019 American Epilepsy Society Annual Meeting	Eisai Inc.
09-Dec-2019	Eisai Presents New Seizure Freedom and Adherence Data Related to Anti-Epileptic Drug FYCOMPA® at the 2019 American Epilepsy Society Annual Meeting	Eisai Inc.
09-Dec-2019	Eisai Presents New Seizure Freedom and Adherence Data Related to Anti-Epileptic Drug FYCOMPA® at the 2019 American Epilepsy Society Annual Meeting	Eisai Inc.
09-Dec-2019	BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors	BJ Bioscience Inc.
09-Dec-2019	Hoth Therapeutics And North Carolina State University Initiate Preclinical Gene Therapy Study For The Treatment Of Asthma	Hoth Therapeutics, Inc.
09-Dec-2019	PDL BioPharma Announces Completion of Strategic Review Process	PDL BioPharma, Inc.
09-Dec-2019	Folium Labs Inc Announces Closing of a New Investment Round and Receives NRC-IRAP Grant from the Government of Canada to Support IP Strategy	Folium Labs Inc.
09-Dec-2019	CNS Pharmaceuticals to Participate in the 8th Annual ROTH Deer Valley Corporate Access Event	CNS Pharmaceuticals, Inc.
09-Dec-2019	Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH	Trovagene, Inc.
09-Dec-2019	AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics	AbbVie
09-Dec-2019	CNS Pharmaceuticals to Participate in the 8th Annual ROTH Deer Valley Corporate Access Event	CNS Pharmaceuticals, Inc.
09-Dec-2019	CNS Pharmaceuticals to Participate in the 8th Annual ROTH Deer Valley Corporate Access Event	CNS Pharmaceuticals, Inc.
09-Dec-2019	Athira Pharma Presents Positive Data for NDX-1017 in Alzheimer's Patients at 2019 Clinical Trials on Alzheimer's Disease (CTAD) Conference	Athira Pharma, Inc.
09-Dec-2019	CNS Pharmaceuticals to Participate in the 8th Annual ROTH Deer Valley Corporate Access Event	CNS Pharmaceuticals, Inc.
09-Dec-2019	InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa	InMed Pharmaceuticals Inc.
09-Dec-2019	Actinium Pharmaceuticals Announces Phase 3 SIERRA Trial Dosimetry Results Support Low Dose Iomab-B for Targeted Lymphodepletion Prior to Adoptive Cell Therapy	Actinium Pharmaceuticals, Inc.
09-Dec-2019	IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020	IDEAYA Biosciences, Inc.